122 related articles for article (PubMed ID: 37951357)
41. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.
Reinhard H; Semler O; Bürger D; Bode U; Flentje M; Göbel U; Gutjahr P; Leuschner I; Maass E; Niggli F; Scheel-Walter HG; Stöckle M; Thüroff JW; Tröger J; Weirich A; von Schweinitz D; Zoubek A; Graf N
Klin Padiatr; 2004; 216(3):132-40. PubMed ID: 15175957
[TBL] [Abstract][Full Text] [Related]
42. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
[TBL] [Abstract][Full Text] [Related]
43. Complex patterns of chromosome 9 alterations including the p16INK4a locus in Wilms tumours.
Natrajan R; Warren W; Messahel B; Reis-Filho JS; Brundler MA; Dome JS; Grundy PE; Vujanic G; Pritchard-Jones K; Jones C
J Clin Pathol; 2008 Jan; 61(1):95-102. PubMed ID: 17369505
[TBL] [Abstract][Full Text] [Related]
44. 16q heterozygosity loss in Wilms' tumour in children and its clinical importance.
Skotnicka-Klonowicz G; Rieske P; Bartkowiak J; Szymik-Kantorowicz S; Daszkiewicz P; Debiec-Rychter M
Eur J Surg Oncol; 2000 Feb; 26(1):61-6. PubMed ID: 10718182
[TBL] [Abstract][Full Text] [Related]
45. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations.
Bardeesy N; Falkoff D; Petruzzi MJ; Nowak N; Zabel B; Adam M; Aguiar MC; Grundy P; Shows T; Pelletier J
Nat Genet; 1994 May; 7(1):91-7. PubMed ID: 8075648
[TBL] [Abstract][Full Text] [Related]
46. Loss of heterozygosity at 7p in Wilms' tumour development.
Powlesland RM; Charles AK; Malik KT; Reynolds PA; Pires S; Boavida M; Brown KW
Br J Cancer; 2000 Jan; 82(2):323-9. PubMed ID: 10646884
[TBL] [Abstract][Full Text] [Related]
47. [Immunohistochemical expression of p53 oncoprotein in Wilms tumour in relation to histological components, histological types and preoperative chemotherapy].
Djuricić S; Djokić D; Vujić D; Basta-Jovanović G; Todorović V; Radojević-Skodrić S; Zdravković S; Vujanić GM
Srp Arh Celok Lek; 2008 Dec; 136 Suppl 4():298-306. PubMed ID: 20804099
[TBL] [Abstract][Full Text] [Related]
48. Immunohistochemical expression of P53 protein in nephroblastoma: a predictor of unfavorable prognosis.
Morgan ED; Yahaya JJ; Ngaiza AI; Othieno E; Livex OA
J Egypt Natl Canc Inst; 2023 Jul; 35(1):23. PubMed ID: 37518096
[TBL] [Abstract][Full Text] [Related]
49. Stromal-type Nephroblastoma with or without Anaplasia in Two Hedgehogs (Atelerix albiventris).
Ueda K; Imada T; Ueda A; Imada M; Ozaki K
J Comp Pathol; 2019 Oct; 172():48-52. PubMed ID: 31690414
[TBL] [Abstract][Full Text] [Related]
50. Clinical, pathological and loss of heterozygosity differences in Wilms tumors between Asian and non-Asian children.
Loke BN; Wong MK; Tawng KD; Kuick CH; Jain S; Lian D; Wagner E; Zou Y; Ganesan V; Sim SW; Lee YT; Chin F; Chan MY; Tan AM; Teh BT; Soh SY; Chang KTE; Loh AHP
Int J Cancer; 2019 Mar; 144(6):1234-1242. PubMed ID: 30362502
[TBL] [Abstract][Full Text] [Related]
51. Responsiveness of chemotherapy based on the histological type and Wilms' tumor suppressor gene mutation in bilateral Wilms' tumor.
Shibata R; Takata A; Hashiguchi A; Umezawa A; Yamada T; Hata J
Pathol Int; 2003 Apr; 53(4):214-20. PubMed ID: 12675764
[TBL] [Abstract][Full Text] [Related]
52. Bloom syndrome in sibs: first reports of hepatocellular carcinoma and Wilms tumor with documented anaplasia and nephrogenic rests.
Jain D; Hui P; McNamara J; Schwartz D; German J; Reyes-Múgica M
Pediatr Dev Pathol; 2001; 4(6):585-9. PubMed ID: 11826367
[TBL] [Abstract][Full Text] [Related]
53. Wilms tumor: an update.
Al-Hussain T; Ali A; Akhtar M
Adv Anat Pathol; 2014 May; 21(3):166-73. PubMed ID: 24713986
[TBL] [Abstract][Full Text] [Related]
54. Preservation of anaplastic features in Wilms' tumors after preoperative chemotherapy.
Alvarez-Silvan AM; Gavilan Carrasco F; Pineda Cuevas G; Andrade Becerra E; Anguita ML; Martinez Caro A; Gracia Valles MC; Maillo Arcega MA
Med Pediatr Oncol; 1989; 17(2):131-3. PubMed ID: 2539546
[TBL] [Abstract][Full Text] [Related]
55. Clinical and biologic significance of nuclear unrest in Wilms tumor.
Hill DA; Shear TD; Liu T; Billups CA; Singh PK; Dome JS
Cancer; 2003 May; 97(9):2318-26. PubMed ID: 12712489
[TBL] [Abstract][Full Text] [Related]
56. Nephroblastoma (Wilms' tumor): a model system of aberrant renal development.
Re GG; Hazen-Martin DJ; Sens DA; Garvin AJ
Semin Diagn Pathol; 1994 May; 11(2):126-35. PubMed ID: 7809506
[TBL] [Abstract][Full Text] [Related]
57. New developments in the pathology of Wilms tumor.
Beckwith JB
Cancer Invest; 1997; 15(2):153-62. PubMed ID: 9095211
[TBL] [Abstract][Full Text] [Related]
58. Significance of proto-oncogene Bcl-X(S/L) expression in Wilms tumor.
Basta-Jovanović G; Radonjic V; Stolic I; Nenadovic M; Brasanac D; Jovanovic D; Radojevic-Skodric S
Ren Fail; 2005; 27(1):13-8. PubMed ID: 15717629
[TBL] [Abstract][Full Text] [Related]
59. Correlations between Histological and Array Comparative Genomic Hybridization Characterizations of Wilms Tumor.
Chiang MR; Kuo CW; Wang WC; Hou TC; Kuo CY; Lu MY; Lai YC
Pathol Oncol Res; 2019 Jul; 25(3):1199-1206. PubMed ID: 30671724
[TBL] [Abstract][Full Text] [Related]
60. Insulin-like growth factor II messenger ribonucleic acid expression in Wilms tumor, nephrogenic rest, and kidney.
Yun K; Molenaar AJ; Fiedler AM; Mark AJ; Eccles MR; Becroft DM; Reeve AE
Lab Invest; 1993 Nov; 69(5):603-15. PubMed ID: 7504120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
